Financhill
Back

Atara Biotherapeutics Quote, Financials, Valuation and Earnings

America's Final Republican President

Click here to see his 2024 election prediction.
Sell
23

ATRA
Atara Biotherapeutics

Last Price:
0.69
Seasonality Move:
-9.8%

7 Day Trial

ALL ACCESS PASS

$ 7

My #1 Coin is...

All the details are on the next page.

Atara Biotherapeutics Price Quote

$0.69

Atara Biotherapeutics Key Stats

Sell
23
Atara Biotherapeutics (ATRA) is a Sell

Day range:
$0.68 - $0.71
52-week range:
$0.20 - $3.02
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
8.52
P/B ratio:
0%

Volume:
524.5K
Avg. volume:
1.1M
1-year change:
-74.73%
Market cap:
$82.4M
Revenue:
$8.6M
EPS:
$-2.62

How Much Does Atara Biotherapeutics Make?

Is Atara Biotherapeutics Growing As A Company?

  • What Is Atara Biotherapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 18.24%
  • What Is Atara Biotherapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Atara Biotherapeutics Stock Price Performance

What Is Atara Biotherapeutics 52-Week High & Low?

Atara Biotherapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Atara Biotherapeutics?

Is Atara Biotherapeutics Cash Flow Positive?

  • What Is ATRA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$193M
  • What Is Atara Biotherapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $2M
  • What Is Atara Biotherapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $123.9M

Atara Biotherapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    ATRA return on invested capital is -2818.48%
  • What Is Atara Biotherapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -107.93%
  • What Is ATRA Return On Equity?
    ROE is a measure of profitability and is -2818.48%

Atara Biotherapeutics Earnings Date & Stock Price

Atara Biotherapeutics Competitors

Atara Biotherapeutics Dividend Yield

Data Unavailable

Atara Biotherapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -16.18%
Revenue: 1823.98% -70.19%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 4.20
Upside from Last Price: 508.7%

Major Shareholders

  • How many ATRA shares are owned by institutional investors?
    86.5M ATRA shares are owned by institutional investors
  • How many ATRA shares are owned by insiders?
    9M ATRA shares are owned by insiders